pentetic acid has been researched along with B-Cell Lymphoma in 8 studies
Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic studies were performed in BALB/c mice." | 1.37 | Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma. ( Huang, Q; Li, C; Liang, D; Lu, W; Lyu, MA; Rosenblum, MG; Wen, X; Zhang, R, 2011) |
| "The aim of this work was to develop a pharmacokinetic model for the analysis of the pharmacokinetics of (111)Inlabeled monoclonal antibodies (mAbs) in B-cell lymphoma patients and to evaluate the model's ability to predict a subsequent radioimmunotherapy by (90)Y-labeled mAbs." | 1.35 | Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data. ( Gleisner, KS; Lindén, O; Nickel, M; Strand, SE; Tennwall, J; Tenvall, J; Wingårdh, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nickel, M | 1 |
| Strand, SE | 1 |
| Lindén, O | 1 |
| Wingårdh, K | 1 |
| Tenvall, J | 1 |
| Tennwall, J | 1 |
| Gleisner, KS | 1 |
| Wen, X | 1 |
| Lyu, MA | 1 |
| Zhang, R | 1 |
| Lu, W | 1 |
| Huang, Q | 1 |
| Liang, D | 1 |
| Rosenblum, MG | 1 |
| Li, C | 1 |
| Govindan, SV | 2 |
| Griffiths, GL | 2 |
| Michel, RB | 1 |
| Andrews, PM | 1 |
| Goldenberg, DM | 2 |
| Mattes, MJ | 1 |
| Sharkey, RM | 1 |
| Fisher, DR | 1 |
| Ellie, E | 1 |
| Vital, A | 1 |
| Steck, AJ | 1 |
| Julien, J | 1 |
| Henry, P | 1 |
| Vital, C | 1 |
| van den Anker-Lugtenburg, PJ | 1 |
| Heule, F | 1 |
| Vanhagen, PM | 1 |
| van Joost, T | 1 |
| Oei, HY | 1 |
| Löwenberg, B | 1 |
| Krenning, EP | 1 |
| Terae, S | 1 |
| Ogata, A | 1 |
| Witzig, TE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized IMMU-LL2: Treatment With 90Y-hLL2 IgG[NCT00421395] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for pentetic acid and B-Cell Lymphoma
| Article | Year |
|---|---|
Development and evaluation of a pharmacokinetic model for prediction of radioimmunotherapy based on pretherapy data.
Topics: Area Under Curve; Humans; Indium Radioisotopes; Kinetics; Linear Models; Lymphoma, B-Cell; Models, S | 2009 |
Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
Topics: Animals; B-Cell Activating Factor; Cell Death; Cell Line, Tumor; Chromatography, Thin Layer; Female; | 2011 |
Use of galactosylated-streptavidin as a clearing agent with 111In-labeled, biotinylated antibodies to enhance tumor/non-tumor localization ratios.
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Biotinylatio | 2002 |
90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Stab | 2003 |
High-grade B-cell cerebral lymphoma in a patient with anti-myelin-associated glycoprotein IgM paraproteinemic neuropathy.
Topics: Aged; Brain; Brain Neoplasms; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; Female; Gadolinium; | 1995 |
Somatostatin receptor scintigraphy in cutaneous malignant lymphomas.
Topics: Administration, Topical; Adrenal Gland Neoplasms; Aged; Aged, 80 and over; Anti-Inflammatory Agents; | 1996 |
Nonenhancing primary central nervous system lymphoma.
Topics: Adult; Biopsy; Brain Neoplasms; Contrast Media; Frontal Lobe; Gadolinium DTPA; Humans; Lymphoma, B-C | 1996 |
The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Lymph | 2000 |